Announcement time of this financial report: 2023-10-17 19:41:35
Shanghai Kaibao Pharmaceutical Co., Ltd. (stock code: 300039) is a comprehensive pharmaceutical enterprise focusing on the research, development, production and sales of modern traditional Chinese medicine. The company has an independent and complete raw material procurement, research and development, production and sales system, and has a number of subsidiaries in different fields, covering respiratory, cardio-cerebrovascular, digestion and other areas of the product line. The company is committed to promoting the development of the great health industry of traditional Chinese medicine, and cooperates with well-known universities and research institutions to continuously promote technological research and innovation. At the same time, the company pays attention to the improvement of marketing and sales ability to achieve coordinated development and business development.
According to Shanghai Kaibao's financial report for the third quarter of 2023, the company's assets totaled 4.403 billion yuan, up from 4.259 billion yuan at the end of last year. Liabilities totaled 581 million yuan, up from 498 million yuan at the end of last year. This shows that while the company is expanding its business scale, its debt has also increased. Goodwill was 9.04 million yuan at the end of this report, the same amount as at the end of last year, indicating that the company has not made any major moves in mergers and acquisitions.
Net assets at the end of the reporting period were 3.822 billion yuan, an increase compared with 3.761 billion yuan at the end of the previous year, indicating an increase in the company's owners' equity. The asset-liability ratio was 13.19% at the end of the reporting period, up from 11.7% at the end of the previous year, which may be due to the increase in corporate liabilities.
In terms of profitability, the company's gross profit margin was 79.14%, up from 78.48% in the same period last year. This shows that the company has done a good job in controlling costs and can maintain a high level of profitability. The net interest rate was 16.96%, up from 14.76% in the same period last year. This shows that the company's net profit as a proportion of operating income has increased, and the company's profitability has been improved. Return on equity (ROE) was 5.17%, up from 3.5% at the end of last year, indicating that the company's profitability has improved.
In terms of operating income, it was 1.154 billion yuan from the beginning of the year to the end of the reporting period, an increase compared with 800 million yuan in the same period last year. This shows that the company's sales business is growing and market demand is increasing. Operating profit was 239 million yuan, up from 144 million yuan in the same period last year. This shows that the company not only expands sales, but also maintains a high profit level. The net profit was 196 million yuan, up from 118 million yuan in the same period last year. This shows that the company's net profit is growing and the company's profitability has been improved.
Overall, Shanghai Kaibao has a good operating condition in the third quarter of 2023, with an increase in operating income and net profit, and an improvement in profitability. At the same time, the company has also increased its investment in R & D, which is beneficial to the long-term development of the company. However, the company's asset-liability ratio has increased, which may put some pressure on the company's financial position. Therefore, when investing, investors need to comprehensively consider the operating indicators of the company and make rational investment decisions.
This article only represents the judgment made by the analyst himself or the analyst on the basis of AI analysis, and can not be used as any investment index, nor does it constitute any investment advice. The original intention of this paper is to help investors analyze and judge the capital market data in the most intuitive and fast way and from the most professional perspective.